ID
34425
Beschrijving
Study ID: 101998 Clinical Study ID: 101998 Study Title: A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier Sponsor GlaxoSmithKline Collaborators N/A Phase Phase 3 Study Recruitment Status Completed Generic Name sumatriptan Trade Name Imitrex ,Imiject ,Imigran Study Indication Migraine Disorders The purpose of this form is to document the current medical condition of the subject. It should be filled out at the screening visit.
Trefwoorden
Versies (3)
- 11-01-19 11-01-19 -
- 13-01-19 13-01-19 -
- 17-01-19 17-01-19 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
17 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Efficacy and Tolerability of TREXIMA Tablets vs. Placebo During Mild Migraine Study ID 101998
Medical Conditions
- StudyEvent: ODM
Similar models
Medical Conditions
- StudyEvent: ODM
C0035173 (UMLS CUI-2)
C0035173 (UMLS CUI [1,2])
C0027365 (UMLS CUI [1,3])
C0035173 (UMLS CUI [1,2])
C1519316 (UMLS CUI [1,3])
C0035173 (UMLS CUI [1,2])
C0028811 (UMLS CUI [1,3])
C0035173 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0035173 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,3])